You just read:

Janssen Enters Into Worldwide Exclusive License and Collaboration Agreement With Protagonist Therapeutics, Inc. for Oral Interleukin-23 Receptor Antagonist Drug Candidate for the Treatment of Inflammatory Bowel Disease

News provided by

Janssen Pharmaceutical Companies

May 30, 2017, 07:00 ET